These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Interferon beta and copolymer-1: mechanism of action and clinical effects in multiple sclerosis]. Losy J Neurol Neurochir Pol; 2000; 34(3 Suppl):63-9. PubMed ID: 10983302 [TBL] [Abstract][Full Text] [Related]
43. [Intravenous immunoglobulins (IVIg) in the treatment of multiple sclerosis]. Achiron A; Miron S Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S41-4. PubMed ID: 10896988 [TBL] [Abstract][Full Text] [Related]
44. Seeing injectable ms therapies differently: they are more similar than different. Johnson KP; Fox RJ; Arnold DL Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129 [No Abstract] [Full Text] [Related]
46. What do we know about the mechanism of action of disease-modifying treatments in MS? Hartung HP; Bar-Or A; Zoukos Y J Neurol; 2004 Sep; 251 Suppl 5():v12-v29. PubMed ID: 15549350 [TBL] [Abstract][Full Text] [Related]
47. Treatment of multiple sclerosis in children and adolescents. Kuntz NL; Chabas D; Weinstock-Guttman B; Chitnis T; Yeh EA; Krupp L; Ness J; Rodriguez M; Waubant E; Expert Opin Pharmacother; 2010 Mar; 11(4):505-20. PubMed ID: 20163265 [TBL] [Abstract][Full Text] [Related]
48. The management of multiple sclerosis in children: a European view. Ghezzi A; Banwell B; Boyko A; Amato MP; Anlar B; Blinkenberg M; Boon M; Filippi M; Jozwiak S; Ketelslegers I; Kornek B; Lim M; Lindstrom E; Nadj C; Neuteboom R; Rocca MA; Rostasy K; Tardieu M; Wassmer E; Catsman-Berrevoets C; Hintzen R Mult Scler; 2010 Oct; 16(10):1258-67. PubMed ID: 20685764 [TBL] [Abstract][Full Text] [Related]
49. [Combined therapy in multiple sclerosis]. García-Merino JA; Blasco-Quítez MR; Ortiz-Benítez P; Puerta C Rev Neurol; 2003 Mar 16-31; 36(6):545-9. PubMed ID: 12652419 [TBL] [Abstract][Full Text] [Related]
50. Immunologic therapy of multiple sclerosis. Arnason BG Annu Rev Med; 1999; 50():291-302. PubMed ID: 10073279 [TBL] [Abstract][Full Text] [Related]
51. [Unresolved problems and the prospects for research in area of the multiple sclerosis: virologic, immunologic and therapeutic aspects]. Mal'tsev DV Lik Sprava; 2014; (5-6):3-19. PubMed ID: 25906643 [TBL] [Abstract][Full Text] [Related]
52. Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. Goodkin DE West J Med; 1994 Sep; 161(3):292-8. PubMed ID: 7975569 [TBL] [Abstract][Full Text] [Related]
54. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis. Banwell B; Tremlett H Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408 [No Abstract] [Full Text] [Related]
55. Lessons from randomised direct comparative trials. Achiron A; Fredrikson S J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860 [TBL] [Abstract][Full Text] [Related]
56. Treatment of multiple sclerosis: recent trials and future perspectives. Noseworthy JH; Gold R; Hartung HP Curr Opin Neurol; 1999 Jun; 12(3):279-93. PubMed ID: 10499173 [TBL] [Abstract][Full Text] [Related]
57. [Causal therapy of multiple sclerosis]. Pöhlau D; Rieks M; Postert T; Hoffmann V; Przuntek H Dtsch Med Wochenschr; 1996 Nov; 121(45):1407-14. PubMed ID: 8964231 [No Abstract] [Full Text] [Related]